clinical trial · NCT04630808
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Nicox Ophthalmics, Inc.·phase3·completed·n = 696
Open Angle GlaucomaOcular HypertensionNCX 470 0.1%Latanoprost 0.005%
brief summary
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
started
Nov 9, 2020
primary completion
Apr 11, 2025
completion
Jun 25, 2025
last updated
Sep 8, 2025
official title
A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol